A novel biologic for the treatment of moderate to severe asthma:Tezepelumab

VernacularTitle:治疗中重度哮喘新型生物制剂:Tezepelumab
Author: Guo-Zhu BAI ; Xi-Le MU ; Ru-Han A ; Yang-Tao WU ; Yong-Xia BAI
Keywords: Tezepelumab; asthma; thymic stromal lymphopoietin(TSLP)
From: The Chinese Journal of Clinical Pharmacology 2024;40(5):741-744
CountryChina
Language:Chinese
Abstract: Tezepelumab(AMG 157/MEDI9929)is a human monoclonal antibody against the epithelial cell-derived cytokine thymic stromal lymphopoietin(TSLP).It is primarily used to treat moderate to severe asthma,particularly in patients with a non-eosinophilic inflammatory phenotype,whose asthma remains uncontrolled despite the use of long-acting beta-agonists and moderate to high doses of inhaled glucocorticoids.This article will summarise the mechanism of action,clinical trial efficacy and safety and tolerability of Tezepelumab in order to provide a comprehensive understanding of the drug and inform clinical work.